Ignite Creation Date:
2025-12-25 @ 3:28 AM
Ignite Modification Date:
2026-05-14 @ 8:29 PM
Study NCT ID:
NCT01650805
Status:
TERMINATED
Last Update Posted:
2014-11-17
First Post:
2012-07-18
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Sponsor:
Ariad Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Chronic Myeloid Leukemia | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Leukemia | View |
| None | Leukemia, Myeloid | View |
| None | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | View |
| None | Neoplasms by Histologic Type | View |
| None | Neoplasms | View |
| None | Lymphoproliferative Disorders | View |
| None | Lymphatic Diseases | View |
| None | Immunoproliferative Disorders | View |
| None | Immune System Diseases | View |
| None | Myeloproliferative Disorders | View |
| None | Bone Marrow Diseases | View |
| None | Hematologic Diseases | View |